RxDoctor Payments Data

David Copenhaver, MD

Pain Medicine · Sacramento, CANPI 1154575462

Payments from drug & device makers

$13,800in general payments, 2019–2025

Across 52 payments — averaging $265.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$10K
  • Medtronic$1K
  • Relievant Medsystems, Inc.$1K
  • Abbott$520
  • Nevro Corp.$226
  • Averitas Pharma Inc.$166
  • plus $171 from 2 others
$800in research payments, 2019–2025

Across 1 payment — averaging $800.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotissue Holdings Inc.$800

What the payments were for

  • Speaking & faculty fees$9,03565%
  • Travel & lodging$3,17023%
  • Food & beverage$1,59412%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vertex13$10,441
Medtronic12$1,265
Relievant Medsystems, Inc.9$1,010
Abbott7$520
Nevro Corp.8$226
Averitas Pharma Inc.1$166
Boston Scientific1$94
Tonix Medicines, Inc.1$77

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,800 in reported general payments places this provider in the 80th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$152,803
Medicare patients
372
Services billed
1,483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine11$3,178
Gabapentin24$1,382
Duloxetine Hcl36$1,245
Oxycodone Hcl25$917

Paid to pharmacies, not to this prescriber.

Other pain medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →